Kymera Investor Day Presentation Deck

Lower Daily Doses of KT-474 Achieved >98% IRAK4 Degradation (MS) Plateau in IRAK4 Reduction after 14 days in PBMC after 100 mg Percent IRAK4 Reduction in PBMC by Mass Spectrometry KYMERA Mean (± SE) Percent IRAK4 Change from Baseline 20 O -20 -40 -60 -80 -100 Mean Day 7 Mean Day 14 p value* ©2021 KYMERA THERAPEUTICS, INC. Day 7 Placebo (n=12) -9% -23% 25 mg QD (n=9) -87% -92% <0.0001 Day 14 50 mg QD (n=9) -93% -95% 100 mg QD (n=9) -97% -98% <0.0001 <0.0001 KYMERA R&D DAY - December 16th, 2021 Placebo 25 mg QD 50 mg QD 100 mg QD 200 mg QD 200 mg QD (n=9) -95% -96% <0.0001 * p-values relative to placebo PAGE 35

View entire presentation